On-demand webcast

Chaired by Mohamad Mohty with Graham Jackson, María-Victoria Manteca, Suzanne Trudel and Salomon Manier, this 1hour 45 minute webcast focuses on providing you with the best decision-making tools to select the optimal therapy for patients with relapsed-refractory multiple myeloma (RRMM). After taking part in the educational activity, you will know who, when, and how to treat RRMM.




Welcome and introduction

Mohamad Mohty

Relapse definition and timing of therapy

Graham Jackson

Optimal sequencing of therapy at first relapse

Mohamad Mohty

Optimal sequencing of therapy beyond first relapse

María-Victoria Mateos

Trial results of anti-CD38 and bispecific antibodies

Salomon Manier

Trial results of conjugated antibodies

Suzanne Trudel

Live faculty Q&A


Summary and close

Mohamad Mohty

Target Audience

Hematologists, oncologists, oncology nurses, and all other HCPs managing RRMM

Learning objectives

After participating in the webcast you will be able to:

  • • Describe the advances in therapeutic targets in RRMM and the associated novel agents
  • • Select optimal and individualized treatment strategies for patients with RRMM


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Educational grant

This independent educational activity was supported by an educational grant from GlaxoSmithKline.


Contact us

Address: Springer Healthcare IME The Campus, 4 Crinan Street London, N1 9XW, UK